Drug Profile
AGEX VASC1
Alternative Names: AGEX-VASC1; Vascular progenitor cell therapy - Serina TherapeuticsLatest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator AgeX Therapeutics
- Developer Serina Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ischaemic heart disorders
Most Recent Events
- 26 Mar 2024 AgeX Therapeutics has merged with Serina Therapeutics to form Serina Therapeutics
- 10 Nov 2022 AGEX VASC1 is still in preclinical trials for Ischaemic heart disorders in USA
- 28 Jul 2022 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in USA (Parenteral)